NCT01587079已完成2 期
A Randomized, Double Blind, (Test Products), Chronic Dosing (7 Days), Four Period, Eight Treatment , Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Five Doses of PT003, One Dose of PT001 and One Dose of PT005 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide 18 µg, Open Label) as Active Control
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 159
- 试验地点
- 1
- 主要终点
- FEV1 AUC 0-12 on Day 7
研究概览
简要总结
The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •40 - 80 years of age
- •Clinical history of COPD with airflow limitation that is not fully reversible
- •Females of non-child bearing potential or females of child bearing potential with negative pregnancy test and acceptable contraceptive methods
- •Current/former smokers with at least a 10 pack-year history of cigarette smoking
- •A measured post-bronchodilator FEV1/FVC ratio of < or = 0.70
- •A measured post-bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values
- •Able to change COPD treatment as required by protocol
排除标准
- •Women who are pregnant or lactating
- •Primary diagnosis of asthma
- •Alpha-1 antitrypsin deficiency as the cause of COPD
- •Active pulmonary diseases
- •Prior lung volume reduction surgery
- •Abnormal chest X-ray not due to the presence of COPD
- •Hospitalized due to poorly controlled COPD within 3 months of Screening
- •Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)
- •Cancer that has not been in complete remission for at least 5 years
- •Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives
- •Other inclusion/exclusion criteria as defined in the protocol
研究组 & 干预措施
PT001
Experimental
PT001 MDI
干预措施: PT001 (Drug)
PT003 (Dose 1)
Experimental
PT003 MDI Dose 1
干预措施: PT003 (Drug)
PT003 (Dose 2)
Experimental
PT003 MDI Dose 2
干预措施: PT003 (Drug)
PT003 (Dose 3)
Experimental
PT003 MDI Dose 3
干预措施: PT003 (Drug)
PT003 (Dose 4)
Experimental
PT003 MDI Dose 4
干预措施: PT003 (Drug)
PT003 (Dose 5)
Experimental
PT003 MDI Dose 5
干预措施: PT003 (Drug)
PT005
Experimental
PT005 MDI
干预措施: PT005 (Drug)
Spiriva® Handihaler®
Active Comparator
Tiotropium Bromide
干预措施: Tiotropium inhalation powder (Drug)
结局指标
主要结局
FEV1 AUC 0-12 on Day 7
时间窗: Day 7
FEV1 AUC 0-12
次要结局
- Peak Change From Baseline in FEV1 on Day 7(Day 7)
- Change From Baseline at Evening 12-hour Post-dose Trough FEV1 on Day 7(Day 7)
- Change From Baseline in Mean Evening Post-dose Daily Peak Flow Readings on Day 7(Day 7)
- Proportion of Subjects Achieving >=12% Improvement in FEV1 on Day 1(Day 1)
- Peak Change From Baseline in FEV1 on Treatment Day 1(Day 1)
- Peak Change From Baseline in Inspiratory Capacity on Day 1(Day 1)
- Change From Baseline in Morning Pre-dose Trough FEV1 on Day 7(Day 7)
- Peak Change From Baseline IC on Day 7(Day 7)
- Time to Onset of Action (>10% Improvement in FEV1) on Day 1(Day 1)
- Change From Baseline in Morning Pre-dose Trough IC on Day 7(Day 7)
- Change From Baseline in Mean Morning Pre-dose Daily Peak Flow Readings on Day 7(Day 7)
- Change From Baseline in Mean Morning Post-dose Daily Peak Flow Readings on Day 7(Day 7)
- Change From Baseline in Mean Evening Pre-dose Daily Peak Flow Readings on Day 7(Day 7)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)NCT01113593Dey45
已完成
2 期
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary HyperhidrosisHyperhidrosisNCT02129660Journey Medical Corporation105
已完成
2 期
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary HyperhidrosisHyperhidrosisNCT02016885Journey Medical Corporation198
已完成
4 期
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.Chronic Obstructive Pulmonary Disease (COPD)NCT04155047Sunovion Respiratory Development Inc.44
已完成
4 期
Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)Pulmonary Disease, Chronic ObstructiveNCT00139932Merck Sharp & Dohme LLC255